Flexion Therapeutics, Inc. (FLXN) Receives “Outperform” Rating from BMO Capital Markets

Flexion Therapeutics, Inc. (NASDAQ:FLXN)‘s stock had its “outperform” rating reiterated by investment analysts at BMO Capital Markets in a research note issued to investors on Monday. They currently have a $37.00 price target on the specialty pharmaceutical company’s stock, up from their prior price target of $35.00. BMO Capital Markets’ price objective would suggest a potential upside of 31.02% from the stock’s current price.

Several other equities research analysts also recently commented on the company. Needham & Company LLC restated a “buy” rating and set a $36.00 price target on shares of Flexion Therapeutics in a research note on Sunday, September 17th. Wells Fargo & Company set a $39.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a research report on Friday. Cantor Fitzgerald set a $40.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a research report on Monday, June 12th. Zacks Investment Research cut Flexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $94.11.

Flexion Therapeutics (FLXN) traded down 2.97% during trading on Monday, reaching $27.40. 1,035,421 shares of the company’s stock were exchanged. Flexion Therapeutics has a 52-week low of $15.93 and a 52-week high of $32.25. The firm’s market cap is $874.20 million. The stock’s 50 day moving average price is $24.85 and its 200 day moving average price is $22.63.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Equities research analysts anticipate that Flexion Therapeutics will post ($3.75) EPS for the current fiscal year.

WARNING: “Flexion Therapeutics, Inc. (FLXN) Receives “Outperform” Rating from BMO Capital Markets” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://ledgergazette.com/2017/10/10/flexion-therapeutics-inc-flxn-price-target-increased-to-37-00-by-analysts-at-bmo-capital-markets.html.

In related news, insider Yamo Deniz bought 1,375 shares of the business’s stock in a transaction dated Thursday, August 31st. The shares were purchased at an average price of $25.40 per share, with a total value of $34,925.00. Following the transaction, the insider now owns 5,000 shares in the company, valued at approximately $127,000. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have bought a total of 5,375 shares of company stock worth $131,575 over the last ninety days. Insiders own 15.98% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. Ardsley Advisory Partners purchased a new stake in shares of Flexion Therapeutics in the 2nd quarter worth $3,338,000. Wasatch Advisors Inc. lifted its holdings in shares of Flexion Therapeutics by 58.7% in the 2nd quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock worth $20,588,000 after buying an additional 376,745 shares during the period. Public Employees Retirement System of Ohio lifted its holdings in shares of Flexion Therapeutics by 69.4% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 41,644 shares of the specialty pharmaceutical company’s stock worth $842,000 after buying an additional 17,066 shares during the period. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Flexion Therapeutics by 13.7% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 63,520 shares of the specialty pharmaceutical company’s stock worth $1,284,000 after buying an additional 7

Several other equities research analysts also recently commented on the company. Needham & Company LLC restated a “buy” rating and set a $36.00 price target on shares of Flexion Therapeutics in a research note on Sunday, September 17th. Wells Fargo & Company set a $39.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a research report on Friday. Cantor Fitzgerald set a $40.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a research report on Monday, June 12th. Zacks Investment Research cut Flexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $94.11.

Flexion Therapeutics (FLXN) traded down 2.97% during trading on Monday, reaching $27.40. 1,035,421 shares of the company’s stock were exchanged. Flexion Therapeutics has a 52-week low of $15.93 and a 52-week high of $32.25. The firm’s market cap is $874.20 million. The stock’s 50 day moving average price is $24.85 and its 200 day moving average price is $22.63.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Equities research analysts anticipate that Flexion Therapeutics will post ($3.75) EPS for the current fiscal year.

WARNING: “Flexion Therapeutics, Inc. (FLXN) Receives “Outperform” Rating from BMO Capital Markets” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://ledgergazette.com/2017/10/10/flexion-therapeutics-inc-flxn-price-target-increased-to-37-00-by-analysts-at-bmo-capital-markets.html.

In related news, insider Yamo Deniz bought 1,375 shares of the business’s stock in a transaction dated Thursday, August 31st. The shares were purchased at an average price of $25.40 per share, with a total value of $34,925.00. Following the transaction, the insider now owns 5,000 shares in the company, valued at approximately $127,000. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have bought a total of 5,375 shares of company stock worth $131,575 over the last ninety days. Insiders own 15.98% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. Ardsley Advisory Partners purchased a new stake in shares of Flexion Therapeutics in the 2nd quarter worth $3,338,000. Wasatch Advisors Inc. lifted its holdings in shares of Flexion Therapeutics by 58.7% in the 2nd quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock worth $20,588,000 after buying an additional 376,745 shares during the period. Public Employees Retirement System of Ohio lifted its holdings in shares of Flexion Therapeutics by 69.4% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 41,644 shares of the specialty pharmaceutical company’s stock worth $842,000 after buying an additional 17,066 shares during the period. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Flexion Therapeutics by 13.7% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 63,520 shares of the specialty pharmaceutical company’s stock worth $1,284,000 after buying an additional 7,667 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Flexion Therapeutics by 3.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company’s stock worth $441,000 after buying an additional 811 shares during the period. 83.26% of the stock is currently owned by institutional investors.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply